New Delhi, March 30 – India's pharmaceutical sector is poised to take a major step towards becoming a globally competitive powerhouse driven by innovation, according to the government, as India Pharma 2026 aims to accelerate the industry's transition from volume-based growth to value and...
biosimilars
department of pharmaceuticals
drug discovery
federation of indian chambers of commerce and industry
generic drugs
global health
healthcare
india
india pharma 2026
innovation
pharmaceutical industry
pharmaceuticals
policy
research and development
supply chains
New Delhi, March 27 Biocon Ltd announced on Friday that Shreehas Tambe has been appointed as CEO & Managing Director, effective April 1, 2026.As the first CEO of the integrated Biocon, he will lead the combined platform encompassing biosimilars and generics, strengthening the company's ability...
The government has proposed the Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) initiative in the 2026-27 Union Budget to position India as a global biopharmaceutical manufacturing hub. The initiative, with a total budget of 10 thousand crore...
biologics
biopharmaceutical manufacturing
biosimilars
economic survey
generic medicines
government policy
healthcare
india
india economy
manufacturing
pharmaceutical exports
pharmaceutical industry
strategic initiative
therapeutic categories
union budget
Washington, March 4 – The U.S. International Trade Commission (USITC) has received a complaint alleging that versions of the cancer drug pertuzumab, which are biosimilars, imported into the United States violate U.S. trade law.Several entities of India’s largest biopharmaceutical company...
biocon biologics inc.
biocon biologics international ltd.
biocon biologics ltd.
biocon biologics uk plc
biocon ltd.
biosimilars
breast cancer treatment
genentech
importation
monoclonal antibody
pertuzumab
section 337 tariff act of 1930
trade remedies
united states international trade commission
usitc
Minister of Chemicals and Fertilizers, Jagat Prakash Nadda, stated that the budgetary allocation of 13 thousand crore rupees for BioPharma SHAKTI and three dedicated Chemical Parks is a strategic investment in India's future. Speaking at the post-Budget webinar on the theme "Sustaining and...
biopharma shakti
biosimilars
central drugs standard control organization
chemical parks
chemical sector
clinical trials
drug fermentation
economic growth
generic medicines
india economy
industrial symbiosis
niper
pharmaceutical industry
trade agreements
viksit bharat
Bengaluru, February 23 Karnataka's BioEconomy is projected to reach USD 39.2 billion in 2025, marking strong growth from previous years and reaffirming the state's leadership position nationally, according to an official report released on Monday.The Karnataka Innovation and Technology Society...
New Delhi, February 12 Biocon announced on Thursday a more than five-fold increase in consolidated net profit to Rs 144 crore for the quarter ended December 2025, driven by gains in its generics and biosimilar business segments.The Bengaluru-based company reported a net profit of Rs 25 crore...